

Title: **Breast Cancer Treatments**

Reference Number: RDF1033-22

Date of Response: 01/12/22

Further to your Freedom of Information Act request, please find the Trust's response(s) below:

I'm hoping that you will be able to help me with Freedom of Information request that I have, please see the questions below:

- 1. In the past 3 months, how many Breast Cancer patients (at any stage) were treated with:*

	Trust (Eastern & Northern Services)
<i>Abemaciclib monotherapy</i>	*
<i>Aromatase inhibitor monotherapy (e.g. anastrozole, exemestane, letrozole)</i>	*
<i>Tamoxifen monotherapy</i>	*
<i>Abemaciclib + Tamoxifen</i>	*

Answer: Please see table above:

* The Trust has considered your request, however to provide you with the information requested would require the manual extraction and manipulation of information from various sources and legacy systems. To carry out this work would exceed the appropriate cost limit as set out in Section 12 (1) of the Freedom of Information Act 2000 and is therefore exempt.

Under the Freedom of Information Act 2000 Section 12 (1) and defined in the Freedom of Information and Data Protection (Appropriate Limit and Fees) Regulations 2004, a public authority is not obliged to comply with a request for information if it estimates that the cost of complying would exceed the appropriate limit. The limit of £450 represents the estimated cost of one person spending two and a half days in determining whether the Trust holds the information, locating, retrieving and extracting that information.

2. In the past 3 months, how many early/locally advanced Breast Cancer (Stages 1 to 3B) patients were treated with:

	Trust (Eastern & Northern Services)
<i>Abemaciclib + Aromatase inhibitor (e.g. anastrozole, exemestane, letrozole)</i>	
<i>Taxane and/or Anthracycline (monotherapy or in combination)</i>	*
<i>Any other active systemic anti cancer therapy</i>	*

Answer: Please see table above.

3. How many patients have been treated for Triple Negative Breast Cancer (any stage) in the past 3 months with the following systemic anti cancer therapies:

- Anthracycline (e.g. doxorubicin or epirubicin) as a single agent
- Atezolizumab +Nab-paclitaxel/Paclitaxel
- Pembrolizumab
- Sacituzumab Govitecan
- Parp Inhibitors (Olaparib/Talazoparib)
- Eribulin as a single agent or in combination
- Capecitabine as a single agent
- Platinum (e.g. carboplatin or cisplatin) as a single agent
- Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent
- Taxane and/or Anthracycline in combination
- Any other active systemic anti-cancer therapy

	Trust (Eastern & Northern Services)
<i>Anthracycline (e.g. doxorubicin or epirubicin) as a single agent</i>	*
<i>Atezolizumab +Nab-paclitaxel/Paclitaxel</i>	*
<i>Pembrolizumab</i>	*
<i>Sacituzumab Govitecan</i>	*
<i>Parp Inhibitors (Olaparib/Talazoparib)</i>	*
<i>Eribulin as a single agent or in combination</i>	*
<i>Capecitabine as a single agent</i>	*
<i>Platinum (e.g. carboplatin or cisplatin) as a single agent</i>	*
<i>Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent</i>	*
<i>Taxane and/or Anthracycline in combination</i>	*
<i>Any other active systemic anti-cancer therapy</i>	*

Answer: Please see table above.